New cancer clinical trial: Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC

Published on: February 20, 2018 at 12:00PM
Condition:   Breast Cancer
Intervention:   Drug: Aromatase Inhibitor and Palbociclib
Sponsor:   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting
http://ift.tt/2GyrIgP